|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Regulation: OK After All
Author(s)Kevin Gopal
London-The National Institute of Clinical Excellence (NICE) has decided that Roche's Xenical (orlistat) should be available from the National Health Service for managing obesity and its related problems, but it should not be viewed as a slimming pill.
Advertisement
Articles in this issue
about 25 years ago
Internet DTC - Minding Your P's & Q'sabout 25 years ago
Regulation: Two-Track Planabout 25 years ago
Policy: Tectonic Shiftabout 25 years ago
Liberated?about 25 years ago
A Matter of Tasteabout 25 years ago
Partnerships: Bargaining Biotechsabout 25 years ago
Pediatric Mandateabout 25 years ago
Genentech's Passion for PatientsAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
The Evolving Relationship Between FDA and Biotech
4
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
5